FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy
The US FDA has granted RMAT designation to Affimed and Artiva Biotherapeutics’ combination therapy for lymphoma.
The US FDA has granted RMAT designation to Affimed and Artiva Biotherapeutics’ combination therapy for lymphoma.
What's Your Reaction?
